National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix M: Prospects for Immunizing Against Parainfluenza Viruses." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
396
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Glezen, W.P. In press. Reactive airway disorders in children: role of respiratory virus infections, Clin. Chest Med.

Glezen, W.P., F.A.Loda, and F.W.Denny. 1982. Parainfluenza viruses. Pp. 441–454 in Viral Infections of Humans, 2nd Edition, A.S.Evans, ed. New York: Plenum.

Glezen W.P., A.L.Frank, L.H.Taber, M.P.Tristan, C.Vallbona, A. Paredes, and J.E.Allison. 1983. Influenza in childhood. Pediatr. Res. 17(12):1029–1032.

Glezen, W.P., A.L.Frank, L.H.Taber, and J.A.Kasel. In press. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J. Infect. Dis.

Merz, D.C., A.Scheid, and P.W.Choppin. 1980. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 151:275–288.

National Institute of Allergy and Infectious Diseases. In press. Report of a Workshop on Respiratory Syncytial Virus and Parainfluenza Viruses. National Institutes of Health.

Parrott, R.H., A.J.Vargosko, H.W.Kim, J.A.Bellanti, and R.M. Chanock. 1962. III. Myxoviruses parainfluenza. Am. J. Public Health 52:907–917.

Portner, A. 1981. The HN glycoprotein of Sendai virus: Analysis of site(s) involved in hemagglutinating and neuraminidase activities. Virology 115:375–384.

Scheid, A., and P.W.Choppin. 1974. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai Virus. Virology 57:475–490.

Scheid, A., A.L.Caliguiri, R.W.Compans, and P.W.Choppin. 1972. Isolation of paramyxovirus glycoprotein. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. Virology 50:640–652.

Smith, C.B., R.H.Purcell, J.A.Bellanti, and R.M.Chanock. 1966. Protective effect of antibody to parainfluenza type 1 virus. N. Engl. J. Med. 275:1145–1152.

Wigley, F.M., M.H.Fruchtman, and R.H.Waldman. 1970. Aerosol immunization of humans with inactivated parainfluenza type 2 vaccine. N. Engl. J. Med. 283:1250–1253.

Page
396
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)